Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

PHARMADANICA A/S Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.1% 1.1%   Bankruptcy risk   0.7% 1.4% 1.3% 0.8% 1.4% 1.3% 7.9% 7.9%   Credit score (0-100)   95 80 80 92 78 79 31 31   Credit rating   AA A A AA A A BB BB   Credit limit (kDKK)   1,806.7 151.8 298.9 1,653.2 174.6 282.7 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   -11.4 -11.0 -20.3 -11.8 -33.1 -26.4 0.0 0.0   EBITDA   -11.4 -11.0 -20.3 -11.8 -33.1 -26.4 0.0 0.0   EBIT   -11.4 -11.0 -20.3 -11.8 -33.1 -26.4 0.0 0.0   Pre-tax profit (PTP)   3,324.0 -777.7 -801.1 477.6 -1,058.0 -15.9 0.0 0.0   Net earnings   3,325.2 -777.0 -792.4 476.0 -1,054.9 -15.1 0.0 0.0   Pre-tax profit without non-rec. items   3,324 -778 -801 478 -1,058 -15.9 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 19,549 18,418 18,285 0.0 0.0   Shareholders equity total   19,649 18,872 18,080 18,556 17,501 17,486 15,986 15,986   Interest-bearing liabilities   1,508 1,518 1,528 1,538 1,548 1,527 0.0 0.0   Balance sheet total (assets)   21,168 20,401 19,618 20,104 19,078 19,038 15,986 15,986   Net Debt   1,224 1,103 1,098 1,000 908 798 -15,986 -15,986     See the entire balance sheet 1000.0 Volume  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   -11.4 -11.0 -20.3 -11.8 -33.1 -26.4 0.0 0.0   Gross profit growth   -251.2% 3.5% -83.6% 42.0% -180.8% 20.1% 0.0% 0.0%   Employees   0 0 0 0 0 0 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   21,168 20,401 19,618 20,104 19,078 19,038 15,986 15,986   Balance sheet change%   18.7% -3.6% -3.8% 2.5% -5.1% -0.2% -16.0% 0.0%   Added value   -11.4 -11.0 -20.3 -11.8 -33.1 -26.4 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 19,549 -1,131 -133 -18,285 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -3.0 -4.0 -5.0 -5.0 -5.0 -5.0 0.0 0.0   1000.0 Profitability  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   17.1% 0.6% 0.1% 2.4% 0.4% 0.6% 0.0% 0.0%   ROI %   17.1% 0.6% 0.1% 2.4% 0.4% 0.6% 0.0% 0.0%   ROE %   18.5% -4.0% -4.3% 2.6% -5.9% -0.1% 0.0% 0.0%   1000.0 Solidity  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Equity ratio %   92.7% 92.5% 92.2% 92.3% 91.7% 91.8% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -10,687.2% -9,985.5% -5,413.1% -8,495.8% -2,746.3% -3,022.3% 0.0% 0.0%   Gearing %   7.7% 8.0% 8.5% 8.3% 8.8% 8.7% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.1% 59.4% 54.2% 0.1% 73.3% 8.6% 0.0% 0.0%   1000.0 Liquidity  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Quick Ratio   0.2 0.3 0.3 0.4 0.4 0.5 0.0 0.0   Current Ratio   0.2 0.3 0.3 0.4 0.4 0.5 0.0 0.0   Cash and cash equivalent   284.6 415.0 430.4 538.3 640.5 729.7 0.0 0.0   1000.0 Capital use efficiency  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   -1,224.6 -1,103.6 -1,089.4 -993.1 -916.6 -799.0 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 0 0 0   EBIT / employee   0 0 0 0 0 0 0 0   Net earnings / employee   0 0 0 0 0 0 0 0